Prosensa was a biotechnology company engaged in the discovery, development and commercialization of RNA-modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne muscular dystrophy (DMD), myotonic dystrophy, and Huntington's disease. Prosensa was acquired by BioMarin Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide. Prosensa entered into an exclusive licensing agreement in 2003 with Leiden University Medical Center (LUMC) for their proprietary RNA modulation exon-skipping technology to develop treatments for DMD, other neuromuscular disorders and indications outside the field of neuromuscular disorders. More information...
According to PR-model, prosensa.eu is ranked 2,227,890th in multilingual Wikipedia, in particular this website is ranked 1,225,789th in English Wikipedia.
The website is placed before elseptimodia.wordpress.com and after canadianarmywife.wordpress.com in the BestRef global ranking of the most important sources of Wikipedia.
